

# Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy

Stalin Bala,  
Sadashivudu Gundeti,  
Vijay Gandhi Linga,  
Lakshmi Srinivas Maddali,  
Raghunadha Rao Digumarti,  
Shantveer G. Uppin<sup>1</sup>

Departments of Medical Oncology,  
<sup>1</sup>Pathology, Nizam's Institute of  
Medical Sciences, Hyderabad,  
Telangana, India

## Address for correspondence:

Dr. Sadashivudu Gundeti,  
Department of Medical  
Oncology, Nizam's Institute of  
Medical Sciences, Punjagutta,  
Hyderabad - 500 082,  
Telangana, India.  
E-mail: drssgundeti@yahoo.com

## INTRODUCTION

Lung cancer is the most common cause of cancer death worldwide of which nonsmall cell lung cancer (NSCLC) predominates.<sup>[1]</sup> While there has been a substantial decline in lung cancer rates in developed countries,<sup>[2]</sup> incidence rates are reportedly rising in newly industrialized and developing countries such as China and India.<sup>[3]</sup> Approximately, 70,000 new cases of lung cancer were diagnosed in India in 2012.<sup>[4]</sup> There is increasing the incidence of lung cancer in never smokers<sup>[5,6]</sup> and also a shift of histology from squamous cell carcinoma to adenocarcinoma.<sup>[7]</sup> The overall ratio of mortality to incidence is high because of presentation in an advanced stage.<sup>[8]</sup>

## ABSTRACT

**Context:** Lung cancer is an important cause of cancer-related deaths worldwide. There is an increasing incidence of lung cancer in never smokers and a shift of histology from squamous cell to adenocarcinoma globally in the recent past. Data on treatment outcomes with newer platinum doublets is scant from India. **Aims:** To study the clinicopathological features, response rates (RRs), progression-free survival (PFS), overall survival (OS), and the 1, 2, and 3 years survival, in patients with advanced nonsmall cell lung cancer (NSCLC). **Materials and Methods:** Data of all patients who received chemotherapy for Stage IIIB and IV NSCLC between January 2010 and June 2014 were retrospectively analyzed. **Statistical Analysis Used:** Univariate analysis for OS was done by plotting Kaplan-Meier curves and the log-rank test was used to calculate *P* values. Logistic regression analysis for OS was carried out using MedCalc statistical software. **Results:** A total of 353 patients received chemotherapy. Of these, 256 were evaluable for outcome parameters. The median age at presentation was 58 years with a male:female ratio of 2.53:1. The smoker:nonsmoker ratio was 1:1. Adenocarcinomatous histology was the most common both in smokers and nonsmokers reported in 70.8% patients. Epidermal growth factor receptor (EGFR) mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase translocation were seen in 35% and 3% of patients, respectively. The RR, median PFS, OS, 1, 2, and 3 years survival were 80%, 8 months, 12.1 months, 51.5%, 12.7%, and 4.2%, respectively. There was no significant survival difference among the treatment regimen used but the response to 1 line chemotherapy impacted survival. Female gender, performance status, and nonsquamous histology were significant predictors of OS (*P* = 0.0443, *P* = 0.0003, *P* = 0.048, respectively). **Conclusions:** There was an increase in the incidence of nonsmokers. Adenocarcinoma was the most common histology in both smokers and nonsmokers. Treatment outcomes in advanced lung cancer were better compared to the past with the advent of newer platinum doublets and EGFR tyrosine kinase inhibitors. The response to first-line chemotherapy significantly impacts outcomes in advanced NSCLC.

**Key words:** Epidermal growth factor receptor, nonsmall cell lung cancer, platinum doublet, survival

Epidermal growth factor receptor (EGFR) mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation are the two main oncogenic drivers identified in the pathogenesis of NSCLC for which targeted therapy is available.<sup>[9,10]</sup> With the advent of EGFR tyrosine kinase inhibitors (TKIs), pemetrexed- and taxane-based platinum doublet, survivals in NSCLC were significantly improved along with marked improvement in quality of life.<sup>[11-13]</sup>

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**For reprints contact:** reprints@medknow.com

**How to cite this article:** Bala S, Gundeti S, Linga VG, Maddali LS, Digumarti RR, Uppin SG. Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy. Indian J Med Paediatr Oncol 2016;37:242-50.

## Access this article online

### Quick Response Code:



**Website:**  
www.ijmpo.org

**DOI:**  
10.4103/0971-5851.195735

Survival and safety data using these newer platinum doublets and targeted therapy are scant in India.

Usage of EGFR TKI in mutation-positive advanced NSCLC patients had resulted in dramatic improvements in response rates (RRs) and survivals, and they had also become a reasonable option in poor performance status who are unfit for chemotherapy.<sup>[14,15]</sup>

The primary objectives of this analysis were to study the RRs, median progression-free survival (PFS), and overall survival (OS) in advanced NSCLC patients treated with platinum-based chemotherapy and targeted therapy with EGFR TKI and ALK inhibitors.

The secondary objectives were to study the demographic, clinicopathological features, toxicity profile and predictors of survival with the newer platinum doublets, and EGFR TKIs.

## MATERIALS AND METHODS

Data from medical records of patients with advanced NSCLC who received chemotherapy between January 2010 and June 2014 were retrieved, and the Institutional Ethical Committee approved the study.

All patients with the diagnosis of advanced NSCLC were analyzed for demographic and clinicopathological features and those patients who had taken at least two cycles of chemotherapy or 2 months of EGFR TKI and had a contrast-enhanced computed tomography (CECT) scan for response evaluation were eligible for the assessment of outcome parameters, namely, RR, PFS, OS, as well as survival rates at 1, 2, and 3 years. Data of patients who did not receive at least two cycles or a response evaluation were censored for outcome parameters.

The diagnosis of NSCLC was confirmed either by fine-needle aspiration or biopsy of lung mass or pleural fluid cytology or cell block analysis. Patients with indeterminate cytology or histology and poorly differentiated histology were diagnosed as NSCLC-not otherwise specified (NSCLC-NOS). The staging investigations included CECT scan of the chest and upper abdomen and bone scan or positron emission tomography-computed tomography (CT) scan. CT scan or magnetic resonance imaging scan of the brain was done whenever appropriate. Other investigations included complete blood counts, liver, and renal functions tests. EGFR mutation analysis was done using a real-time polymerase chain reaction. ALK screening was done through immunohistochemistry (IHC) and positive cases were confirmed by fluorescent *in situ* hybridization. Staging was done according to AJCC 7<sup>th</sup> Edition of lung cancer staging.<sup>[16]</sup>

Informed consent was taken from all patients before administration of chemotherapy patients were treated

with various regimens administered intravenously or orally. Platinum doublets used were cisplatin 75 mg/m<sup>2</sup> D1/carboplatin (AUC 5) D1 + pemetrexed 500 mg/m<sup>2</sup> D1<sup>[11]</sup>/paclitaxel 175 mg/m<sup>2</sup> D1<sup>[12]</sup>/albumin-bound paclitaxel 260 mg/m<sup>2</sup> D1<sup>[17]</sup>/gemcitabine 1 g/m<sup>2</sup> D1 and D8.<sup>[11]</sup> EGFR TKIs and ALK inhibitors used were gefitinib 250 mg or erlotinib 150 mg once daily and crizotinib 250 mg once daily. Vitamin B<sub>12</sub> and folate supplementation were given before and during pemetrexed-based chemotherapy and antihistamines, and steroids were given prophylactically before paclitaxel administration. Chemotherapy dosages were modified in patients with renal and liver dysfunction.

Patients were also given radiotherapy (RT) wherever it was indicated, with palliative intent, for primary or metastatic sites. Patients with anemia received transfusions, febrile neutropenia received growth factor support with antibiotics. Pleural fluid drainage was done in patients with symptomatic pleural effusion. Patients were given a maximum of 4–6 cycles of chemotherapy followed by continuous or switch maintenance until progression, based on the response evaluation and EGFR mutation status.

Response evaluation was performed after every 2–3 cycles of chemotherapy by a clinical examination and CECT of the chest and upper abdomen.

### The following response criteria were used

Revised RECIST guideline version 1.1 was used to define response evaluation criteria.<sup>[12]</sup>

A complete response (CR) was defined as disappearance of all the lesions on radiology. Partial response (PR) was defined as a decrease of 30% in the sum of the longest diameter of all target lesions. Progressive disease (PD) was defined as an increase of 20% in the sum of the longest diameters of the target lesions or appearance of a new lesion at any time during or after therapy. Stable disease (SD) was defined as patients who did not fit into either PR or PD.

PFS was defined as the time from start of chemotherapy to the time that PD was documented, death, or lost to follow-up. OS was defined as the time from start of chemotherapy to death due to any cause or lost to follow-up.

### Statistical methods

GraphPad Software Quick Cals online calculator was used to calculate the *P* values for the categorical and continuous variables. For continuous variables, the *P* value was calculated using the unpaired *t*-test to compare the means. For categorical data such as stage, smoking, sex, performance status, and RRs, the two-tailed *P* value was calculated using Fisher's exact test and 2 × 2 contingency table.

Univariate and multivariate analysis were done to assess the effect of age, sex, smoking status, performance status,

stage, and chemotherapy regimens on OS. Patients were also compared for all outcome parameters with respect to whether they were treated with a platinum-based doublet or EGFR TKI.

GraphPad Prism software for Windows Version 6 was used to plot the Kaplan–Meier curves for PFS and OS (GraphPad Software, La Jolla California USA, www.graphpad.com). Univariate analysis for OS was done by plotting Kaplan–Meier curves, and the log-rank test was used to calculate *P* values. Logistic regression analysis for OS was carried out using MedCalc demo version statistical software 16.4.3 using the same independent variables after coding (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2016). *P* < 0.05 was considered as statistically significant.

## RESULTS

### Patient characteristics

Three hundred and fifty-three patients who received chemotherapy for advanced NSCLC between January 2010 and August 2014 were retrospectively analyzed. The flow diagram was shown in Figure 1. The median age of patients was 58 years (range, 19–82) with a male: female ratio of 2.53:1. The baseline characteristics of all patients are in Table 1.

Of this, 256 patients took at least 2 cycles of chemotherapy and had radiological response evaluation. These patients were eligible for the evaluation of outcome parameters such as RR, median PFS, OS, 1 year, 2 years, and 3 years survival. 97 patients who had received <2 cycles or were lost to follow-up without having a radiological response evaluation were not eligible for outcome parameters.

Cough (76.2%) was the most common symptom at presentation followed by dyspnea, weight loss, anorexia, and chest pain. Hemoptysis and hoarseness of voice are present in 24.6% and 10.7% patients, respectively. Central nervous system symptoms at presentation were seen in 20 (5.6%) patients, of which headache was the most common.

Forty-three (12.1%) patients were started on antituberculosis treatment outside before diagnosis of NSCLC at our institute. The median duration of delay in diagnosis is 3 months (1–12 months). Smoker: nonsmoker ratio in the present study was 1:1 with smoking history seen in 168 (66%) males and 9 (9%) females, respectively. The median age at presentation in smokers and nonsmokers was 60 years (35–82) and 55 years (19–78), respectively.

The diagnosis of NSCLC was based on biopsy in 200 (56.7%) and cytology in 153 (43.3%) patients. The most common histological diagnosis was adenocarcinoma 250 (70.8%) followed by squamous cell carcinoma 66 (18.8%), NSCLC-NOS (8.5%), adenosquamous (1.1%), and large cell carcinoma (0.8%).

IHC was done in 212/353 (60%) patients and TTF-1, napsyn, and p63 were positive, respectively, in 68% (148/212), 50% (32/64), and 27% (39/143) tested for immunohistochemical markers. Out of the 266 adenocarcinoma and 50 squamous cell carcinoma patients, smoking history is seen in 47.4% and 70%, respectively. The median duration of pack-years of smoking was 30 pack years. Clinicopathological features were tabulated in Table 2.

**Table 1: Demographic characteristics of all patients (n=353)**

Character	n (%)
Age in years	58 (19–82)
Males	60 (30–82)
Females	55 (19–78)
Sex ratio	2.53:1
Males	253 (71.7)
Females	100 (28.3)
ECOG PS	
<2	229 (64.9)
≥2	124 (35.1)
Smoking/tobacco usage	177 (50.1)
Males	172 (97.1)
Females	5 (2.9)
Stage	
IIIB	25 (7)
IV	328 (93)

ECOG – Eastern Cooperative Oncology Group; PS – Performance status

**Table 2: Clinicopathologic features (n=353)**

Character	n (%)
Symptoms	
Cough	269 (76.2)
Dyspnea	194 (54.9)
Hemoptysis	87 (24.6)
Hoarseness of voice	38 (10.7)
Chest pain	98 (27.7)
Weight loss and anorexia	179 (50.7)
Histology	
Adenocarcinoma	250 (70.9)
Squamous cell carcinoma	66 (18.7)
NSCLC NOS	30 (8.5)
Adenosquamous	4 (1.1)
Large cell carcinoma	3 (0.8)
EGFR mutation (n=134)	
Positive	47 (35)
Negative	87 (65)
Type of exon mutated (n=47)	
Exon 19	38 (80.9)
Exon 20	2 (4.2)
Exon 21	7 (14.9)
EML4-ALK translocation (n=99)	3 (3)

NSCLC-NOS – Non-small cell lung cancer-not otherwise specified;

EGFR – Epidermal growth factor receptor; ALK – Anaplastic lymphoma kinase;

EML4 – Echinoderm microtubule-associated protein-like 4

The comorbidities of the patients were tabulated in Table 3. Opposite lung, bone, pleural effusion, adrenal gland, liver, and brain metastases were seen in 126 (38.6%), 109 (33.4%), 107 (32.8%), 57 (17.4%), 35 (10.7%), and 33 (10.1%) patients, respectively.

#### Epidermal growth factor receptor mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase translocation analysis

EGFR mutation analysis was done in 134 of 303 nonsquamous patients. Of the 134 patients, 46 (34.3%) were EGFR mutation positive. The most common exon mutated was 19 (78.7%). EML4-ALK translocation was seen in 3 (3%) out of the 99 patients tested.

#### Treatment results for all patients

One hundred and thirty-four patients had at least a CR (3/256) or PR (131/256), with an overall RR of 52.3% (134/256). SD and PD were seen in 71/256 (27.7%) and 51/256 (20%) patients, respectively. The median PFS was 8 months (range 2–58) and OS was 12.1 months (range 2–70). The median PFS and OS were shown in Figure 2 and Figure 3 respectively. The 1 year, 2 years, and 3 years survival was 51.5%, 12.9%, and 4.2%, respectively. Treatment outcomes for all patients were tabulated in Table 4.

Out of 256 patients who were evaluated for outcome parameters, 205 (80%) patients who had PR or SD on response evaluation were eligible for maintenance therapy. Of the 205 patients, 105 (51.2%) patients received continuation or switch maintenance. Fifty-eight (22.6%) patients were able to receive second-line chemotherapy at disease progression. The median number of cycles of initial chemotherapy was 4 cycles followed which maintenance was started based on EGFR mutation status and the median duration of follow-up was 11.2 months (range, 2–70 months).

The overall RR, median PFS, and OS in EGFR mutation positive patients treated with EGFR TKI were 82%, 13.5 months (range, 2.8–36), and 16.8 months (range, 4.8–40), respectively.

#### Univariate and multivariate analysis of variables for overall survival

Univariate analysis was performed for age (<60 years vs. ≥60 years), gender (male vs. female), smoking status (yes vs. no), Stage (IIIB vs. IV), performance status (<2 vs. ≥2), histology (nonsquamous vs. squamous), treatment regimens used for OSs.

On univariate analysis, the strongest predictors for OS were female gender, performance status, and nonsquamous histology ( $P = 0.04$ ,  $P = 0.0003$ , and  $P = 0.048$  respectively). Age, stage, smoking status, and treatment regimens did not predict significantly for OS ( $P = 0.5257$ ,  $P = 0.4854$ ,

$P = 0.404$ , and  $P = 0.1502$ , respectively). On multivariate analysis also, female gender, performance status, and nonsquamous histology were significant for OS ( $P = 0.0415$ ,  $P = 0.0018$ , and  $P = 0.0231$ , respectively). Comparison of present study with our previous data was tabulated in Table 5.

#### Effect of chemotherapy regimen and treatment response on overall survival

The outcomes for patients treated with various doublets were analyzed. The median OS for patients treated with pemetrexed-based platinum, taxane-based platinum, and EGFR TKI were 12.3, 7.4, and 12.5, respectively which was not significant statistically ( $P = 0.1502$ ). OS based on chemotherapy regimen was shown in Figure 4.

The median OS for patients who had CR/PR, SD, and PD were 13.1, 8, and 4.1 months, respectively which was statistically significant ( $P \leq 0.0001$ ). OS based on response to 1st line is shown in Figure 5.

#### Radiotherapy

Out of 256 patients, 54 (21%) patients received RT. Forty-nine (19.1%) patients received RT for extrathoracic disease (brain and bone) and 5 (1.9%) patients received RT for locoregional disease.

#### Adverse events following chemotherapy and tyrosine kinase inhibitors

The most common adverse events were fatigue (10%), vomiting (9%). Grade 2–3 neuropathy and alopecia is seen in 12.2% and 8.1% with taxane-based treatment.

**Table 3: Comorbid conditions of all patients (n=353)**

Comorbid condition	n (%)
HTN	36 (10.2)
DM	24 (6.8)
DM/HTN	44 (12.5)
CAD	15 (4.2)
Viral hepatitis	6 (1.7)

HTN – Hypertension; DM – Diabetes mellitus; CAD – Coronary artery disease

**Table 4: Treatment outcomes for all patients (n=256)**

Parameter	n (%)
Complete response	3 (1.2)
Partial response	131 (51.1)
Stable disease	71 (27.7)
Progressive disease	51 (20)
PFS (months)	8 (2–58)
OS (months)	12.1 (2–68)
1 year OS	132/256 (51.5)
2 year OS	33/256 (12.9)
3 year OS	11/256 (4.2)

PFS – Progression-free survival; OS – Overall survival

Myelosuppression is seen in 8.1% and 4% patients treated with taxane and pemetrexed-based platinum treatment, respectively. Two patients had megaloblastic anemia. Skin rash is the most common adverse effect with EGFR TKI, seen in 32% of patients of which 4.5% needed dose reduction or stoppage of drug.

**DISCUSSION**

This is a retrospective analysis of patients with advanced lung cancer. Typically, palliation of symptoms and most objective responses in lung cancer are reported to occur during the first 2 cycles of chemotherapy. Hence, in our study, we had evaluated all patients who received at least 2 cycles of chemotherapy and had an objective response evaluation for outcome parameters.

Of the 353 patients, 256 patients were evaluable for outcome parameters. Data were inadequate in 97 patients (did not receive at least 2 cycles or had no radiological response evaluation). These patients were excluded from this analysis. The median age at presentation of 58 years and gender ratio of 2.53:1 in the present study is similar to other Indian Studies by Krishnamurthy *et al.*<sup>[19]</sup> and Noronha

*et al.*<sup>[20]</sup> Comparison of demographic characteristics with other Indian studies was tabulated in Table 6. There was a significant proportion of increase in lung cancer among nonsmokers. Nonsmokers were more likely to be female<sup>[21-23]</sup> and had a lower median age at diagnosis compared to smokers.<sup>[20]</sup> Adenocarcinoma was the most common histology in both smokers and nonsmokers accounting for 71% of all cases, which is higher, compared to the studies by Krishnamurthy *et al.*<sup>[19]</sup> and Noronha *et al.*,<sup>[20]</sup> in which adenocarcinoma was seen in 50% and 44% patients, respectively. Squamous cell carcinoma was seen only in one-sixth of patients, in contrast to the reports by Dey *et al.*<sup>[24]</sup> and Behera and Balamugesh<sup>[25]</sup> in 2004, who reported squamous cell carcinoma is most common histology. In approximately 8.5% of patients, subtype of NSCLC could not be established as tissue was insufficient for immunohistochemical studies. A significant proportion (43/353; 12.1%) of patients received antituberculous treatment before the diagnosis of lung cancer based on clinical and radiological findings causing a median delay in diagnosis of 3 months, similar to the paper by Noronha *et al.*<sup>[20]</sup>


**Table 5: Univariate analysis of treatment variables (n=256)**

Variable	n (%)	PFS (months)	OS (months)	HR (95% CI)	
				P for PFS	P for OS
Age (years)					
<60	134 (52.3)	6.4	8.6	0.3004	0.5257
≥60	122 (47.7)	8.4	12.2	0.8801 (0.6849–1.121)	1.081 (0.8481–1.387)
Gender					
Male	185 (72.2)	6.7	8.4	0.0047	0.0443
Female	71 (27.7)	11	13.1	1.468 (1.128–1.879)	0.759 (0.5889–0.9893)
Smoking					
Yes	117 (45.7)	6.85	8.7	0.2024	0.4046
No	139 (54.3)	8.1	12.6	0.8547 (0.6643–1.088)	1.108 (0.8700–1.423)
Stage					
IV	239 (93.3)	7.8	12	0.3663	0.4854
IIIB	17 (6.7)	12	13.2	1.2151 (0.7876–1.927)	1.189 (0.7465–1.862)
PS					
≥2	81 (31.7)	5.8	6.4	0.0071	0.0003
<2	175 (68.3)	8.4	12.6	1.425 (1.120–1.979)	1.611 (1.304–2.348)
Histology					
Nonsquamous	218 (85.1)	8.4	12.3	0.0652	0.048
Squamous	38 (14.9)	5.8	7.4	1.402 (0.9815–2.260)	0.6968 (0.4213–1.003)


PFS – Progression-free survival; OS – Overall survival; CI – Confidence interval; HR – Hazard ratio; PS – Performance status

**Table 6: Comparison with other Indian studies**


	Present study	Krishna Murthy <i>et al.</i> <sup>[19]</sup>	Dey <i>et al.</i> <sup>[24]</sup>	Noronha <i>et al.</i> <sup>[20]</sup>
Median age (years)	58	56	60	56
Male:female	2.53:1	3.5:1	4.14:1	3.5:1
Smokers:nonsmokers	1:1	1.52:1	2.7:1	1.08:1
Adenocarcinoma (%)	70.9	49.1	30.81	43.8
Squamous cell carcinoma (%)	18.7	18.3	35.09	26.2



**Figure 1:** Flow diagram of study patients. Other regimens\* – gemcitabine-platinum doublet, carboplatin and etoposide, cisplatin, and etoposide. NSCLC – Nonsmall cell lung cancer; EGFR – Epidermal growth factor receptor; TKI – Tyrosine kinase inhibitor; ALK – Anaplastic lymphoma kinase



**Figure 2:** Kaplan–Meier estimates of progression-free survival for all patients. PFS – Progression-free survival



**Figure 3:** Kaplan–Meier estimates of overall survival for all patients. OS – Overall survival

EGFR mutational analysis was done in only 50% of the patients with nonsquamous histology. The nonavailability of mutation analysis in the 50% patients is due to use of cytology as the diagnostic modality in some cases and inadequate biopsy tissue. Among those tested, 35% (47/134) of patients were EGFR mutation positive, which is comparable to reports by Bhatt *et al.*, Veldore *et al.*, Mehta and Choughule *et al.*, who reported the frequency of EGFR mutation between 25% and 40%,<sup>[26-29]</sup> respectively. Exon 19 was the most common mutation seen in 78% of patients. EGFR mutation status comparison with other studies was tabulated in Table 7. The presence of EML4-ALK translocation in 3% (3/99) of patients tested for translocation is similar to the reports by Kwak *et al.*<sup>[10]</sup> and Doval *et al.*<sup>[30]</sup>


The overall RR (complete and PR) of 52.3% observed in the present study is significantly higher compared to a

previous study from this center by Rajappa *et al.*<sup>[31]</sup> This is because of use of newer platinum doublets and EGFR TKI in most of the patients. The survival rates at 1, 2, and 3 years were also markedly improved with the use of these chemotherapeutic agents. Among the various regimens used, treatment with pemetrexed-based platinum doublet and EGFR TKI had higher PFS and OS, compared to treatment with taxane- and gemcitabine-based doublet (OS: 12.3, 12.5, 7.9 and 5.9 months, respectively, for pemetrexed, EGFR TKI, taxane, and gemcitabine,  $P = 0.2183$ ). Although this was statistically insignificant, Grade 2–3 neuropathy, myelosuppression, and alopecia were higher in patients treated with taxane-based platinum doublet, compared to pemetrexed and EGFR TKI, suggesting pemetrexed and EGFR TKI were better tolerated and less toxic regimens with significant benefits on quality of life.

**Table 7: Comparison of epidermal growth factor receptor mutation status in present study with other studies**

	Mehta (n=402)	Choughule <i>et al.</i> (n=1018)	Veldore <i>et al.</i> (n=1036)	Bhatt <i>et al.</i> (n=106)	Noronha <i>et al.</i> (n=111)	Western study Rosell <i>et al.</i>	Present study (n=134)
EGFR positive (%)	32	25	40.3	39.6	35.1	16.6	35
Exon 18 (%)	-	6	1.8	-	2.6	-	-
Exon 19 (%)	76	53	24.6	-	74.4	62.2	78.7
Exon 20 (%)	-	3	1.6	-	-	-	4.3
Exon 21 (%)	24	38	12.8	-	23	37.8	17

EGFR – Epidermal growth factor receptor




**Figure 4:** Kaplan–Meier estimates of survival (overall survival) of platinum doublets and Epidermal growth factor receptor tyrosine kinase inhibitor. EGFR – Epidermal growth factor receptor; TKI – Tyrosine kinase inhibitor

iPASS<sup>[12]</sup> and iTARGET<sup>[13]</sup> trials reported an overall RR of 52% and 65%–70%, respectively in EGFR mutation positive patients treated with gefitinib. The ORR of 82% in EGFR mutation positive patients treated with gefitinib or erlotinib was higher in this analysis compared to these reports, but the OS seen in our study was slightly lower compared to iPASS trial.<sup>[12]</sup>

Univariate and multivariate analysis for various predictors of survival showed that female gender, performance status at presentation, and nonsquamous histology predicted for OS significantly. The possible reason for better survival in females and nonsquamous histology would be due to more number of mutation positive patients and use of targeted therapy in these patients. The response to first-line chemotherapy also had a significant impact on the survival with patients having complete or PR had better OS than SD and PD. This was similar to a meta-analysis by Johnson *et al.*<sup>[32]</sup> and a study by Sirohi *et al.*,<sup>[33]</sup> who reported that patients with PR after 2 cycles have a better response and longer survival compared to patients with SD.

Compared to the previous data from this center presented by Rajappa *et al.* in 2008,<sup>[31]</sup> there was an increase in incidence of women and never-smokers and



**Figure 5:** Kaplan–Meier estimates of survival (overall survival) of all patients based on response to first-line treatment. CR – Complete response; PR – Partial response; SD – Stable disease; PD – Progressive disease

also a marked improvement in PFS, OS and survival rates at 1, 2, and 3 years, showing the effectiveness of newer platinum doublets compared to I generation platinum doublet. Comparison with previous data by Rajappa *et al* was shown in Table 8. Only 58 patients received second-line chemotherapy at progression, and the probable reasons were deterioration of PS or lack of adequate finances.

The drawbacks of the present study are that it is retrospective, with limited data on adverse events of chemotherapy and lack of information on quality of life. There is underreporting of both hematologic and nonhematologic adverse events because of inadequate documentation in the case files.

## CONCLUSIONS

The findings of our study have significant implications for clinical practice. There was an increase in the incidence of lung cancer in never smokers. Adenocarcinoma was the most common histology of lung cancer. The survival in lung cancer is significantly increased with the use of newer platinum doublets and targeted therapy compared to the past. Female gender and good performance status were strong predictors for better survivals in advanced NSCLC. Pemetrexed and EGFR TKI were well-tolerated agents with less adverse events.

**Table 8: Comparison of present study with our previous data**

Parameter	Rajappa <i>et al.</i> (2002–2006) <sup>3,21</sup>	Present study (2010–2014)
Age in years (range)	58 (16–88)	58 (19–82)
Gender	4:1	2.53:1
Smoking (%)	191/294 (65)	177/353 (50.1)
PS		
<2	191/294 (65)	229/353 (64.9)
≥2	103/294 (35)	124/353 (35.1)
Stage		
IIIB	170/294 (58)	25/353 (7)
IV	124/294 (42)	328/353 (93)
Overall response (%)	69	80
PFS (months)	6 (2–70)	8
OS (months)	7 (2–72)	12.1
1 year survival (%)	29.8	51.5
2 years survival (%)	9.7	12.9

PFS – Progression free survival; OS – Overall survival; PS – Performance status

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

1. Detterbeck FC, Decker RH, Tanoue L, Lilenbaum RC. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. *Cancer: Principles and Practice of Oncology*. 4<sup>th</sup> ed. Philadelphia: Wolters Kluwer; 2015. p. 495-535.
2. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, *et al.* Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J Natl Cancer Inst* 2008;100:1672-94.
3. Kanavos P. The rising burden of cancer in the developing world. *Ann Oncol* 2006;17 Suppl 8:viii15-23.
4. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lung Cancer [Database on the internet]. International Agency for Research on Cancer, World Health Organization; 2013. Available from: [http://www.globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://www.globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). [Last cited on 2014 Jan 08].
5. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, *et al.* Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. *J Clin Oncol* 2006;24:2245-51.
6. Samet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, Thun MJ, *et al.* Lung cancer in never smokers: Clinical epidemiology and environmental risk factors. *Clin Cancer Res* 2009;15:5626-45.
7. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising. *Int J Cancer* 2005;117:294-9.
8. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11-30.
9. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, *et al.* Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 2009;361:958-67.
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, *et al.* Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693-703.
11. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, *et al.* Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2008;26:3543-51.
12. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, *et al.* Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57.
13. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, *et al.* First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *J Clin Oncol* 2008;26:2442-9.
14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isoobe H, *et al.* Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8.
15. Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, *et al.* Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. *Oncologist* 2007;12:90-8.
16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, *et al.* The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2:706-14.
17. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, *et al.* Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. *J Clin Oncol* 2012;30:2055-62.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, *et al.* New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-47.
19. Krishnamurthy A, Vijayalakshmi R, Gadigi V, Ranganathan R, Sagar TG. The relevance of "Nonsmoking-associated lung cancer" in India: A single-centre experience. *Indian J Cancer* 2012;49:82-8.
20. Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, George K, *et al.* Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience. *Indian J Cancer* 2012;49:74-81.
21. Gao YT, Blot WJ, Zheng W, Ershow AG, Hsu CW, Levin LI, *et al.* Lung cancer among Chinese women. *Int J Cancer* 1987;40:604-9.
22. Shimizu H, Tominaga S, Nishimura M, Urata A. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. *Jpn J Clin Oncol* 1984;14:595-600.
23. Jindal SK, Malik SK, Dhand R, Gujral JS, Malik AK, Datta BN. Bronchogenic carcinoma in Northern India. *Thorax* 1982;37:343-7.
24. Dey A, Biswas D, Saha SK, Kundu S, Kundu S, Sengupta A. Comparison study of clinicoradiological profile of primary lung cancer cases: An Eastern India experience. *Indian J Cancer* 2012;49:89-95.
25. Behera D, Balamugesh T. Lung cancer in India. *Indian J Chest Dis Allied Sci* 2004;46:269-81.
26. Bhatt AD, Pai R, Rebekah G, Nehru GA, Dhananjayan S, Samuel A, *et al.* Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status. *Indian J Cancer* 2013;50:94-101.
27. Veldore VH, Rao RM, Kakara S, Pattanayak S, Tejaswi R, Sahoo R, *et al.* Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. *Indian J Cancer* 2013;50:87-93.

28. Choughule A, Noronha V, Joshi A, Desai S, Jambhekar N, Utture S, *et al.* Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. *Indian J Cancer* 2013;50:107-11.
29. Mehta J. Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population. *Indian J Cancer* 2013;50:102-6.
30. Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, *et al.* Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. *Onco Targets Ther* 2015;8:117-23.
31. Rajappa S, Gundeti S, Talluri MR, Digumarti R. Chemotherapy for advanced lung cancer: A 5-year experience. *Indian J Cancer* 2008;45:20-6.
32. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, *et al.* Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. *Lancet Oncol* 2006;7:741-6.
33. Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, *et al.* Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. *J Thorac Oncol* 2007;2:735-40.